Dasatinib

Recent Results in Cancer Research

Volumn 184, Issue , 2010, Pages 83-102

  Lindauer, Markus ^a   Hochhaus, Andreas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; BCR ABL PROTEIN; BOSUTINIB; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 3A4; DASATINIB; DEXAMETHASONE; EPHRIN RECEPTOR; ERYTHROMYCIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; IMATINIB; INTERFERON; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; PHENOBARBITAL; PHENYTOIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE YES; PROTON PUMP INHIBITOR; RIFAMPICIN; STEM CELL FACTOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ASCITES; ASTHENIA; BACTERIAL INFECTION; BLAST CELL CRISIS; BLEEDING; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM METASTASIS; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COUGHING; CYTOGENETICS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENZYME INHIBITION; EPITHELIUM TUMOR; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENERALIZED EDEMA; HEADACHE; HEMATOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOKALEMIA; HYPOMAGNESEMIA; IN VITRO STUDY; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; MYALGIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STEM CELL TRANSPLANTATION; STOMATITIS; SYSTEMIC MASTOCYTOSIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION; VOMITING;

CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; ONCOGENE PROTEINS V-ABL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SRC-FAMILY KINASES; THIAZOLES;

EID: 77953659574     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-01222-8_7     Document Type: Review

References (68)

1. Akhmetshina A, Dees C, Pileckyte M et al (2008) Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22: 2214-2222
2. Apperley (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018-1029
3. Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820
4. Borthakur G, Kantarjian HM, O'Brien S, et al (2008) Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). J Clin Oncol 26:15S:abstr. 7013
5. Bose S, Deininger M, Gora-Tybor J et al (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362-3367
6. Bristol-Myers Squibb (2007) Dasatinib (Sprycel) Summary of product characteristics and prescribing information
7. Chang Q, Jorgensen C, Pawson T et al (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99:1074-1082
8. Chen Z, Lee FY, Bhalla KN et al (2006) Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (Dasatinib). Mol Pharmacol 69: 1527-1533
9. Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532-4539
10. Cortes J, Rousselot P, Kim DW et al (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213
11. Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008:1-8
12. Cross NCP, Reiter A (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 119:199-206
13. Daley GQ, Van Etten RA (1990) Induction of chronic myelogenous leukaemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824
14. Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566
15. Druker BJ, Guilhot F, O'Brien S et al (2006) Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417 (Pubitemid 44903745)
16. Evans TRJ, Morgan JA, Van den Abbeele AD, et al (2005) Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol 23:16S:abstr. 3034
17. Fabarius A, Giehl M, Rebacz B et al (2008) Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93: 1145-1154
18. Faderl S, Kantarjian HM, Thomas DA et al (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36:263-273
19. Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319-326
20. Gambacorti-Passerini C, Gasser M, Ahmed S et al (2005) Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19:1267-1269
21. Gambacorti C, Cortes J, Kim DW, et al (2007) Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood 110:abstr. 472
22. Giles FJ, DeAngelo DJ, Baccarani M et al (2008) Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 35(Suppl 1):S1-S17
23. Gratwohl A, Hermans J, Goldman JM et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352:1087-1092
24. Guilhot F, Chastang C, Michallet M et al (1997) Interferon a-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223-229
25. Guilhot F, Apperley J, Kim DW et al (2007a) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143-4150 (Pubitemid 46743375)
26. Guilhot F, Apperley JF, Kim DW, et al (2007b) Efficacy of dasatinib in patients with. accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 110:abstr. 470
27. Hehlmann R, Heimpel H, Hasford J et al (1994) Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064-4077
28. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710
29. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316
30. Hirota S, Isozaki K, Moriyama Y et al (1998) Gainof-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580 (Pubitemid 28067289)
31. Hochhaus A (2007) Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. Ann Oncol 18(Suppl 9): ix58-ix63
32. Hochhaus A, Erben P, Ernst T et al (2007a) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 44:15-24
33. Hochhaus A, Kantarjian HM, Baccarani M et al (2007b) Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309 (Pubitemid 46425867)
34. Hochhaus A, Baccarani M, Deininger M et al (2008a) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200-1206
35. Hochhaus A, Neubauer A, Mueller MC, et al (2008b) Imatinib discontinuation after imatinib/ interferon alpha combination therapy is associated with continuous responses in the majority of patients. Haematologica 93:abstr. 0927
36. Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226-2238 (Pubitemid 46424242)
37. Jabbour E, Cortes J, O'Brien S et al (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance Semin Hematol 44:25-31
38. Jayson GC, Parker GJM, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973-981
39. Johnson FM, Saigal B, Talpaz M et al (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924-6932
40. Johnson FM, Chiappori A, Burris H, et al (2007) A phase I study (CA180021-segment 2) of dasatinib in patients (pts) with advanced solid tumors. J Clin Oncol 25:18S:abstr. 14042
41. Kantarjian H, Pasquini R, Hammerschlak N et al (2007) Dasatinib or high-dose imatinib study for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 109:5143-5150 (Pubitemid 46890528)
42. Kopetz S, Shah AN, Gallick GE (2007) Src continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-7236
43. Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475-486
44. Lindahl P, Johannsson BR (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-246
45. Lombardo LJ, Lee FY, Chen P et al (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661
46. Nam S, Kim D, Cheng JQ et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65:9185-9189
47. Nowell P, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497
48. O'Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505
49. Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase II study. Blood 110: 2309-2315
50. Park SI, Zhang JZ, Phillips KA et al (2008) Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68: 3323-3333
51. Pasquini R, Ottmann OG, Goh YT, et al (2007) Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph (+) ALL resistant or intolerant to imatinib: one-year results of CA180-035. J Clin Oncol 25:18S:abstr. 7025
52. Porkka K, Simonsson B, Dombret H, et al (2007) Efficacy of dasatinib in patients with Philadelphiachromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015). Blood 110:abstr. 2810
53. Porkka K, Koskenvesa P, Lundan T et al (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukaemia. Blood 112:1005-1012
54. Quintas-Cardama A, Kantarjian H, O'Brien S et al (2007a) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914
55. Quintas-Cardama A, Kantarjian H, O'Brien S, et al (2007b) Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukaemia. Haematologica 92(Suppl 1):abstr. 0359
56. Schittenhelm MM, Shiraga S, Schroeder A et al (2006) Dasatinib (BMS-354825), a dual SRC/ ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473-481
57. Serrels A, Macpherson IRJ, Evans TRJ et al (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5:3014-3022
58. Shah NP (2005) Loss of response to imatinib: mechanisms and management. The American society of hematology education program book. pp 183-187
59. Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
60. Shah NP, Lee FY, Luo R et al (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinibresistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108(1):286-291
61. Shah NP, Kantarjian HM, Kim DM et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204-3212
62. Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res 67:2800-2808
63. Song L, Morris M, Bagui T et al (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66:5542-5548
64. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1998) Long-term follow-up of the Italian trial of interferon-a versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541-1548
65. Talpaz M, Shah NP, Kantarjian H et al (2006) dasatinib in imatinib-resistant philadelphia chromosome- positive leukemias. N Engl J Med 354: 2531-2541 (Pubitemid 43882349)
66. Tokarski JS, Newitt JA, Chang CYJ et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790-5797
67. Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3907-3915
68. Yu EY, Wilding G, Posadas E, et al (2008) Dasatinib in patients with hormone refractory progressive prostate cancer: a phase II study. J Clin Oncol 26:15S:abstr. 5165